The round was led by Silicon Valley venture capital firm Khosla Ventures. Synchron is the leader in minimally invasive implantable brain computer interface (BCI) technology, which utilizes the jugular vein to access the brain. Synchron has already commenced a clinical trial in Australia that has so far enrolled four patients with paralysis who have undergone implantation and are being assessed for their ability to control digital devices through thought to improve their functional independence.

Other investors include Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital (Michael Auerbach), re.Mind Capital (Christian Angermayer), as well as individuals Arani Bose (Penumbra) and Thomas Reardon. Existing investors also participated in the round including NeuroTechnology Investors, METIS innovative, and the University of Melbourne. This funding brings the total amount raised since company formation to $59 million, including support from the U.S. and Australian governments.

Synchron, a brain interface platform company, is a leader in the field of implantable neural interface technology. The company is already in the clinical stage with a commercial neuroprosthesis for the treatment of paralysis and is developing the first endovascular implantable neuromodulation therapy. Future applications may include the potential to diagnose and treat conditions of nervous system, including Parkinson's disease, epilepsy, depression, and hypertension, as well as non-medical solutions.